T cell immunoglobulin and immune receptor tyrosine-based inhibitory motif domain (TIGIT) is a co-inhibitory receptor, which is highly expressed in a variety of malignant tumors.It can inhibit T cells and NK cells, and plays a key role in regulating immune response and tumor immune escape.TIGIT is closely related to the growth, metastasis and prognosis of urologic tumors, and its overexpression is associated with tumor progression and poor prognosis.Currently, TIGIT-based urologic tumors treatment strategies include monoclonal antibody therapy and combined immunotherapy, such as combination therapy with PD-1/PD-L1 and other drugs.Experimental and clinical studies on TIGIT are also being carried out and significant progress has been made.Therefore, TIGIT is expected to become a new target for immunotherapy and a biomarker for predicting the prognosis of patients with urologic tumors.This article reviews the research progress of TIGIT in urologic tumors.